Literature DB >> 9121608

The neurosteroid pregnenolone sulfate blocks deficits induced by a competitive NMDA antagonist in active avoidance and lever-press learning tasks in mice.

C Mathis1, E Vogel, B Cagniard, F Criscuolo, A Ungerer.   

Abstract

The neurosteroid pregnenolone sulfate (PREG-S) has been shown to modulate positively NMDA receptor activity and to have memory enhancing properties in mice. The present study was designed to evaluate the effects of post-training administration of PREG-S, alone or in combination with D-2-amino-5-phosphonovalerate (D-AP5), a competitive NMDA receptor antagonist, in Y-maze avoidance and appetitively motivated lever-press learning tasks and in a traction reflex test in mice. Intracerebroventricular (i.c.v.) administration of PREG-S (0.01-0.1 nmol/mouse) blocked the selective retention deficits induced by 0.02 nmol D-AP5 in the Y-maze avoidance task. PREG-S (0.1 nmol, i.c.v.) also blocked the retention deficits induced by 0.02 nmol D-AP5 in the lever-press task. Post-training administration of PREG-S alone (0.001-0.1 nmol, i.c.v.) had no effect on retention performance in the Y-maze and the lever-press tasks. PREG-S (1-10 nmol, i.c.v.) significantly reduced the impairment of the traction reflex induced by 2 nmol D-AP5. The ability of PREG-S to block retention performance deficits as well as motor impairment induced by D-AP5 is in agreement with its positive modulatory action at NMDA receptors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9121608     DOI: 10.1016/s0028-3908(96)00041-x

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  18 in total

Review 1.  Neurosteroids and cholinergic systems: implications for sleep and cognitive processes and potential role of age-related changes.

Authors:  Olivier George; Monique Vallée; Michel Le Moal; Willy Mayo
Journal:  Psychopharmacology (Berl)       Date:  2006-01-17       Impact factor: 4.530

2.  Memory-enhancing effects of secreted forms of the beta-amyloid precursor protein in normal and amnestic mice.

Authors:  H Meziane; J C Dodart; C Mathis; S Little; J Clemens; S M Paul; A Ungerer
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

3.  The synthetic enantiomer of pregnenolone sulfate is very active on memory in rats and mice, even more so than its physiological neurosteroid counterpart: distinct mechanisms?

Authors:  Y Akwa; N Ladurelle; D F Covey; E E Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

4.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

5.  Low concentrations of neuroactive steroids alter kinetics of [3H]ifenprodil binding to the NMDA receptor in rat frontal cortex.

Authors:  Tobias Johansson; Per-Anders Frändberg; Fred Nyberg; Pierre Le Grevès
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

6.  Neuropsychopharmacological properties of neuroactive steroids in depression and anxiety disorders.

Authors:  Daniela Eser; Cornelius Schüle; Elena Romeo; Thomas C Baghai; Flavia di Michele; Augusto Pasini; Peter Zwanzger; Frank Padberg; Rainer Rupprecht
Journal:  Psychopharmacology (Berl)       Date:  2005-10-25       Impact factor: 4.530

7.  Neuroprotection by the synthetic neurosteroid enantiomers ent-PREGS and ent-DHEAS against Aβ₂₅₋₃₅ peptide-induced toxicity in vitro and in vivo in mice.

Authors:  Fadia El Bitar; Johann Meunier; Vanessa Villard; Marion Alméras; Kathiresan Krishnan; Douglas F Covey; Tangui Maurice; Yvette Akwa
Journal:  Psychopharmacology (Berl)       Date:  2014-01-31       Impact factor: 4.530

8.  A post-training intrahippocampal anxiogenic dose of the neurosteroid pregnenolone sulfate impairs passive avoidance retention.

Authors:  E Martín-García; M Pallarés
Journal:  Exp Brain Res       Date:  2008-07-30       Impact factor: 1.972

Review 9.  Pregnenolone, dehydroepiandrosterone, and schizophrenia: alterations and clinical trials.

Authors:  Michael S Ritsner
Journal:  CNS Neurosci Ther       Date:  2010       Impact factor: 5.243

10.  Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.

Authors:  Christine E Marx; Jimmy Lee; Mythily Subramaniam; Attilio Rapisarda; Dianne C T Bautista; Edwin Chan; Jason D Kilts; Robert W Buchanan; Eu Pui Wai; Swapna Verma; Kang Sim; Jayaraman Hariram; Rajesh Jacob; Richard S E Keefe; Siow Ann Chong
Journal:  Psychopharmacology (Berl)       Date:  2014-07-17       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.